Literature DB >> 11428873

Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea.

R Alonso1, S Gros, T Peláez, D García-de-Viedma, M Rodríguez-Créixems, E Bouza.   

Abstract

Recurrence is a major complication of Clostridium difficile associated diarrhoea, especially in human immunodeficiency virus (HIV) positive patients, and it is important to distinguish between relapse and re-infection in recurrent episodes. The aim of our study was to analyse C. difficile isolates obtained from HIV-positive patients with recurrent diarrhoea in order to distinguish between relapse and re-infection. This analysis was based on the study of DNA similarities among isolates obtained from different episodes within each patient. Relapses occurred in 64% of patients, 32% suffered re-infections and a combination of relapse plus re-infection was seen in 4%. DNA typing methods can be useful tools to characterize recurrent episodes of C. difficile associated disease. Copyright 2001 The Hospital Infection Society.

Entities:  

Mesh:

Year:  2001        PMID: 11428873     DOI: 10.1053/jhin.2001.0943

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  10 in total

1.  In vitro activity of linezolid against Clostridium difficile.

Authors:  T Peláez; R Alonso; C Pérez; L Alcalá; O Cuevas; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

Review 3.  Clostridium difficile infection in patients with HIV/AIDS.

Authors:  Paul J Collini; Ed Kuijper; David H Dockrell
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

4.  Association of relapse of Clostridium difficile disease with BI/NAP1/027.

Authors:  Jane W Marsh; Rangolee Arora; Jessica L Schlackman; Kathleen A Shutt; Scott R Curry; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

5.  Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.

Authors:  Kentaro Oka; Takako Osaki; Tomoko Hanawa; Satoshi Kurata; Mitsuhiro Okazaki; Taki Manzoku; Motomichi Takahashi; Mamoru Tanaka; Haruhiko Taguchi; Takashi Watanabe; Takashi Inamatsu; Shigeru Kamiya
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

6.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 7.  Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients.

Authors:  Daniel L Raines; Fred A Lopez
Journal:  Curr Gastroenterol Rep       Date:  2011-08

8.  Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea.

Authors:  Yajarayma Tang-Feldman; Susan Mayo; Joseph Silva; Stuart H Cohen
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county.

Authors:  T Norén; T Akerlund; E Bäck; L Sjöberg; I Persson; I Alriksson; L G Burman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report.

Authors:  Jonathan Miner; M Monem Gillan; Philip Alex; Michael Centola
Journal:  BMC Gastroenterol       Date:  2005-01-24       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.